Cytogenetic effects in children treated with methylphenidate

Randa A. El-Zein, Sherif Abdel-Rahman, Matthew J. Hay, Mirtha S. Lopez, Melissa L. Bondy, Debra L. Morris, Marvin S. Legator

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

In recent years there has been a surge in methylphenidate (Ritalin) use for treatment of attention deficit/hyperactivity disorder (ADHD) in children. However, there is a paucity of information on whether this drug poses any potential health risks, such as mutagenicity or carcinogenicity, for humans. To address this issue, we investigated whether this central nervous system stimulant produces cytogenetic abnormalities in pediatric patients at therapeutic levels. In a population composed of twelve children treated with therapeutic doses of methylphenidate, we analyzed three cytogenetic endpoints in peripheral blood lymphocytes obtained before and three months after initiation of treatment with this drug. In all participants, treatment induced a significant 3, 4.3 and 2.4-fold increase in chromosome aberrations, sister chromatid exchanges and micronuclei frequencies, respectively (P=0.000 in all cases). These findings warrant further investigations of the possible health effects of methylphenidate in humans, especially in view of the well-documented relationship between elevated frequencies of chromosome aberrations and increased cancer risk.

Original languageEnglish (US)
Pages (from-to)284-291
Number of pages8
JournalCancer Letters
Volume230
Issue number2
DOIs
StatePublished - Dec 18 2005

Fingerprint

Methylphenidate
Cytogenetics
Chromosome Aberrations
Central Nervous System Stimulants
Therapeutics
Sister Chromatid Exchange
Health
Attention Deficit Disorder with Hyperactivity
Pharmaceutical Preparations
Lymphocytes
Pediatrics
Population
Neoplasms

Keywords

  • ADHD
  • Children
  • Chromosomal aberrations
  • Genotoxicity
  • Methylphenidate

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

El-Zein, R. A., Abdel-Rahman, S., Hay, M. J., Lopez, M. S., Bondy, M. L., Morris, D. L., & Legator, M. S. (2005). Cytogenetic effects in children treated with methylphenidate. Cancer Letters, 230(2), 284-291. https://doi.org/10.1016/j.canlet.2005.01.003

Cytogenetic effects in children treated with methylphenidate. / El-Zein, Randa A.; Abdel-Rahman, Sherif; Hay, Matthew J.; Lopez, Mirtha S.; Bondy, Melissa L.; Morris, Debra L.; Legator, Marvin S.

In: Cancer Letters, Vol. 230, No. 2, 18.12.2005, p. 284-291.

Research output: Contribution to journalArticle

El-Zein, RA, Abdel-Rahman, S, Hay, MJ, Lopez, MS, Bondy, ML, Morris, DL & Legator, MS 2005, 'Cytogenetic effects in children treated with methylphenidate', Cancer Letters, vol. 230, no. 2, pp. 284-291. https://doi.org/10.1016/j.canlet.2005.01.003
El-Zein, Randa A. ; Abdel-Rahman, Sherif ; Hay, Matthew J. ; Lopez, Mirtha S. ; Bondy, Melissa L. ; Morris, Debra L. ; Legator, Marvin S. / Cytogenetic effects in children treated with methylphenidate. In: Cancer Letters. 2005 ; Vol. 230, No. 2. pp. 284-291.
@article{e4bcb4927c0c45ffbfd326b21dd61c05,
title = "Cytogenetic effects in children treated with methylphenidate",
abstract = "In recent years there has been a surge in methylphenidate (Ritalin) use for treatment of attention deficit/hyperactivity disorder (ADHD) in children. However, there is a paucity of information on whether this drug poses any potential health risks, such as mutagenicity or carcinogenicity, for humans. To address this issue, we investigated whether this central nervous system stimulant produces cytogenetic abnormalities in pediatric patients at therapeutic levels. In a population composed of twelve children treated with therapeutic doses of methylphenidate, we analyzed three cytogenetic endpoints in peripheral blood lymphocytes obtained before and three months after initiation of treatment with this drug. In all participants, treatment induced a significant 3, 4.3 and 2.4-fold increase in chromosome aberrations, sister chromatid exchanges and micronuclei frequencies, respectively (P=0.000 in all cases). These findings warrant further investigations of the possible health effects of methylphenidate in humans, especially in view of the well-documented relationship between elevated frequencies of chromosome aberrations and increased cancer risk.",
keywords = "ADHD, Children, Chromosomal aberrations, Genotoxicity, Methylphenidate",
author = "El-Zein, {Randa A.} and Sherif Abdel-Rahman and Hay, {Matthew J.} and Lopez, {Mirtha S.} and Bondy, {Melissa L.} and Morris, {Debra L.} and Legator, {Marvin S.}",
year = "2005",
month = "12",
day = "18",
doi = "10.1016/j.canlet.2005.01.003",
language = "English (US)",
volume = "230",
pages = "284--291",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Cytogenetic effects in children treated with methylphenidate

AU - El-Zein, Randa A.

AU - Abdel-Rahman, Sherif

AU - Hay, Matthew J.

AU - Lopez, Mirtha S.

AU - Bondy, Melissa L.

AU - Morris, Debra L.

AU - Legator, Marvin S.

PY - 2005/12/18

Y1 - 2005/12/18

N2 - In recent years there has been a surge in methylphenidate (Ritalin) use for treatment of attention deficit/hyperactivity disorder (ADHD) in children. However, there is a paucity of information on whether this drug poses any potential health risks, such as mutagenicity or carcinogenicity, for humans. To address this issue, we investigated whether this central nervous system stimulant produces cytogenetic abnormalities in pediatric patients at therapeutic levels. In a population composed of twelve children treated with therapeutic doses of methylphenidate, we analyzed three cytogenetic endpoints in peripheral blood lymphocytes obtained before and three months after initiation of treatment with this drug. In all participants, treatment induced a significant 3, 4.3 and 2.4-fold increase in chromosome aberrations, sister chromatid exchanges and micronuclei frequencies, respectively (P=0.000 in all cases). These findings warrant further investigations of the possible health effects of methylphenidate in humans, especially in view of the well-documented relationship between elevated frequencies of chromosome aberrations and increased cancer risk.

AB - In recent years there has been a surge in methylphenidate (Ritalin) use for treatment of attention deficit/hyperactivity disorder (ADHD) in children. However, there is a paucity of information on whether this drug poses any potential health risks, such as mutagenicity or carcinogenicity, for humans. To address this issue, we investigated whether this central nervous system stimulant produces cytogenetic abnormalities in pediatric patients at therapeutic levels. In a population composed of twelve children treated with therapeutic doses of methylphenidate, we analyzed three cytogenetic endpoints in peripheral blood lymphocytes obtained before and three months after initiation of treatment with this drug. In all participants, treatment induced a significant 3, 4.3 and 2.4-fold increase in chromosome aberrations, sister chromatid exchanges and micronuclei frequencies, respectively (P=0.000 in all cases). These findings warrant further investigations of the possible health effects of methylphenidate in humans, especially in view of the well-documented relationship between elevated frequencies of chromosome aberrations and increased cancer risk.

KW - ADHD

KW - Children

KW - Chromosomal aberrations

KW - Genotoxicity

KW - Methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=27744471323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744471323&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2005.01.003

DO - 10.1016/j.canlet.2005.01.003

M3 - Article

C2 - 16297714

AN - SCOPUS:27744471323

VL - 230

SP - 284

EP - 291

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -